VeClose Five Year Follow-Up Extension Study

NCT ID: NCT03455699

Last Updated: 2019-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

114 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The VeClose Five Year Follow-up Extension Study will continue to assess the safety and efficacy of the VenaSeal Closure System for the long term effect on closure of the great saphenous vein by conducting a follow-up visit at five years post index procedure/enrollment in the VeClose study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Great Saphenous Vein (GSV) With Venous Reflux Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: VenaSeal SCS

Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).

VenaSeal SCS

Intervention Type DEVICE

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Active Comparator: RFA

Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).

ClosureFast Radiofrequency Ablation (RFA)

Intervention Type DEVICE

Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.

Experimental: Roll-in (VenaSeal SCS)

Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.

Roll-In (VenaSeal SCS)

Intervention Type DEVICE

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VenaSeal SCS

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention Type DEVICE

ClosureFast Radiofrequency Ablation (RFA)

Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.

Intervention Type DEVICE

Roll-In (VenaSeal SCS)

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VenaSeal Sapheon Closure System VSCS ClosureFast VenaSeal Sapheon Closure System VSCS Roll-in

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Enrolled in the VeClose study.
2. Able and willing to complete the required 5 year study visit including Duplex ultrasound exam.
3. Able and willing to provide written informed consent prior to study specific data collection.

Exclusion Criteria

1\. Withdrew consent from the VeClose study.
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Endovascular

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nick Morrison, MD

Role: PRINCIPAL_INVESTIGATOR

Morrison Vein Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Morrison Vein Institute

Scottsdale, Arizona, United States

Site Status

GBK Cosmetic Laser Dermatology

San Diego, California, United States

Site Status

Radiology Imaging Associates (RIA)

Greenwood Village, Colorado, United States

Site Status

Prairie Education & Research Cooperative

Springfield, Illinois, United States

Site Status

MD Laser Skin & Vein Institute

Hunt Valley, Maryland, United States

Site Status

Vein Institute of Buffalo

North Tonawanda, New York, United States

Site Status

Inovia Vein Speciality Center

Bend, Oregon, United States

Site Status

Sentara Vascular Specialists

Virginia Beach, Virginia, United States

Site Status

Lake Washington Vascular

Bellevue, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Morrison N, Gibson K, Vasquez M, Weiss R, Cher D, Madsen M, Jones A. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):321-330. doi: 10.1016/j.jvsv.2016.12.005. Epub 2017 Mar 6.

Reference Type BACKGROUND
PMID: 28411697 (View on PubMed)

Kolluri R, Gibson K, Cher D, Madsen M, Weiss R, Morrison N. Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2016 Oct;4(4):407-15. doi: 10.1016/j.jvsv.2016.06.017. Epub 2016 Aug 8.

Reference Type BACKGROUND
PMID: 27638993 (View on PubMed)

Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):978-989. doi: 10.1016/j.jvsv.2019.12.080. Epub 2020 Mar 20.

Reference Type DERIVED
PMID: 32205125 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP-1011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Venclose digiRF System Post Market Study
NCT05504070 ENROLLING_BY_INVITATION NA
Compont - Varicose Veins of the Lower Extremities
NCT06387264 ACTIVE_NOT_RECRUITING NA